|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu MC and Yuan JM: Environmental factors
and risk for hepatocellular carcinoma. Gastroenterology 127 (5
Suppl 1). S72–S78. 2004.
|
|
3
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu MD, Jia LH, Liu HB, Zhang KH and Guo
GH: Sorafenib in combination with transarterial chemoembolization
for hepatocellular carcinoma: A meta-analysis. Eur Rev Med
Pharmacol Sci. 20:64–74. 2016.PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei R, Huang GL, Zhang MY, Li BK, Zhang
HZ, Shi M, Chen XQ, Huang L, Zhou QM, Jia WH, et al: Clinical
significance and prognostic value of microRNA expression signatures
in hepatocellular carcinoma. Clin Cancer Res. 19:4780–4791. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Callegari E, Gramantieri L, Domenicali M,
D'Abundo L, Sabbioni S and Negrini M: MicroRNAs in liver cancer: A
model for investigating pathogenesis and novel therapeutic
approaches. Cell Death Differ. 22:46–57. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao Y, Zhang SG, Wang ZH and Liao JC:
Down-regulation of miR-342-3p in hepatocellular carcinoma tissues
and its prognostic significance. Eur Rev Med Pharmacol Sci.
21:2098–2102. 2017.PubMed/NCBI
|
|
15
|
Zhao XQ, Liang B, Jiang K and Zhang HY:
Down-regulation of miR-655-3p predicts worse clinical outcome in
patients suffering from hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 21:748–752. 2017.PubMed/NCBI
|
|
16
|
Lu D, Wu Y, Wang Y, Ren F, Wang D, Su F,
Zhang Y, Yang X, Jin G, Hao X, et al: CREPT accelerates
tumorigenesis by regulating the transcription of cell-cycle-related
genes. Cancer Cell. 21:92–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carvalho B, Postma C, Mongera S, Hopmans
E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthäi A,
Cuesta MA, et al: Multiple putative oncogenes at the chromosome 20q
amplicon contribute to colorectal adenoma to carcinoma progression.
Gut. 58:79–89. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng G, Yu M, Chen LC, Moore D, Kurisu W,
Kallioniemi A, Waldman FM, Collins C and Smith HS: Amplifications
of oncogene erbB-2 and chromosome 20q in breast cancer determined
by differentially competitive polymerase chain reaction. Breast
Cancer Res Treat. 40:271–281. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Wang S, Kang W, Liu C, Dong Y,
Ren F, Wang Y, Zhang J, Wang G, To KF, et al: CREPT facilitates
colorectal cancer growth through inducing Wnt/β-catenin pathway by
enhancing p300-mediated β-catenin acetylation. Oncogene.
37:3485–3500. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng G, Li W, Zuo B, Guo Z, Xi W, Wei M,
Chen P, Wen W and Yang AG: High expression of CREPT promotes tumor
growth and is correlated with poor prognosis in colorectal cancer.
Biochem Biophys Res Commun. 480:436–442. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li W, Zheng G, Xia J, Yang G, Sun J, Wang
X, Wen M, Sun Y, Zhang Z and Jin F: Cell cycle-related and
expression-elevated protein in tumor overexpression is associated
with proliferation behaviors and poor prognosis in non-small-cell
lung cancer. Cancer Sci. 109:1012–1023. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma J, Ren Y, Zhang L, Kong X, Wang T, Shi
Y and Bu R: Knocking-down of CREPT prohibits the progression of
oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc
expression. PLoS One. 12:e01743092017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Qiu H, Hu W, Li S and Yu J: RPRD1B
promotes tumor growth by accelerating the cell cycle in endometrial
cancer. Oncol Rep. 31:1389–1395. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Z, Zhang W, Jiang K, Chen B, Wang K,
Lao L, Hou C, Wang F, Zhang C and Shen H: MicroRNA-300 regulates
the ubiquitination of PTEN through the CRL4BDCAF13 E3
ligase in osteosarcoma cells. Mol Ther Nucleic Acids. 10:254–268.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He J, Feng X, Hua J, Wei L, Lu Z, Wei W,
Cai H, Wang B, Shi W, Ding N, et al: miR-300 regulates cellular
radiosensitivity through targeting p53 and apaf1 in human lung
cancer cells. Cell Cycle. 16:1943–1953. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu J, Xie F, Bao X, Chen W and Xu Q:
miR-300 inhibits epithelial to mesenchymal transition and
metastasis by targeting Twist in human epithelial cancer. Mol
Cancer. 13:1212014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin K, Chen H, Zuo Q, Huang C, Zhao R, Yu
X, Wang Y, Zhang Y, Chang Z and Li B: CREPT and p15RS regulate cell
proliferation and cycling in chicken DF-1 cells through the
Wnt/β-catenin pathway. J Cell Biochem. 119:1083–1092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Liu C, Duan X, Ren F, Li S, Jin
Z, Wang Y, Feng Y, Liu Z and Chang Z: CREPT/RPRD1B, a recently
identified novel protein highly expressed in tumors, enhances the
β-catenin. TCF4 transcriptional activity in response to Wnt
signaling. J Biol Chem. 289:22589–22599. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pan XP, Wang HX, Tong DM, Li Y, Huang LH
and Wang C: miRNA-370 acts as a tumor suppressor via the
downregulation of PIM1 in hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 21:1254–1263. 2017.PubMed/NCBI
|
|
31
|
Wang R, Yu Z, Chen F, Xu H, Shen S, Chen
W, Chen L, Su Q, Zhang L, Bi J, et al: miR-300 regulates the
epithelial-mesenchymal transition and invasion of hepatocellular
carcinoma by targeting the FAK/PI3K/AKT signaling pathway. Biomed
Pharmacother. 103:1632–1642. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou F, Li Y, Hao Z, Liu X, Chen L, Cao Y,
Liang Z, Yuan F, Liu J, Wang J, et al: MicroRNA-300 inhibited
glioblastoma progression through ROCK1. Oncotarget. 7:36529–36538.
2016.PubMed/NCBI
|
|
33
|
He FY, Liu HJ, Guo Q and Sheng JL: Reduced
miR-300 expression predicts poor prognosis in patients with
laryngeal squamous cell carcinoma. Eur Rev Med Pharmacol Sci.
21:760–764. 2017.PubMed/NCBI
|
|
34
|
Ge W, Han C, Wang J and Zhang Y: MiR-300
suppresses laryngeal squamous cell carcinoma proliferation and
metastasis by targeting ROS1. Am J Transl Res. 8:3903–3911.
2016.PubMed/NCBI
|
|
35
|
Ma F, Wang SH, Cai Q, Jin LY, Zhou D, Ding
J and Quan ZW: Long non-coding RNA TUG1 promotes cell proliferation
and metastasis by negatively regulating miR-300 in gallbladder
carcinoma. Biomed Pharmacother. 88:863–869. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang JQ, Chen S, Gu JN, Zhu Y, Zhan Q,
Cheng DF, Chen H, Deng XX, Shen BY and Peng CH: MicroRNA-300
promotes apoptosis and inhibits proliferation, migration, invasion
and epithelial-mesenchymal transition via the Wnt/β-catenin
signaling pathway by targeting CUL4B in pancreatic cancer cells. J
Cell Biochem. 119:1027–1040. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang L and Yu P: miR-300 promotes
proliferation and EMT-mediated colorectal cancer migration and
invasion by targeting p53. Oncol Rep. 36:3225–3232. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xue Z, Zhao J, Niu L, An G, Guo Y and Ni
L: Up-regulation of miR-300 promotes proliferation and invasion of
osteosarcoma by targeting BRD7. PLoS One. 10:e01276822015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang J, Luo H, Du J and Liu Y:
MicroRNA-300 plays as oncogene by promoting proliferation and
reducing apoptosis of liver cancer cells by targeting MDC1. Int J
Clin Exp Pathol. 9:1231–1239. 2016.
|
|
40
|
Olatunji I: Potential application of tumor
suppressor microRNAs for targeted therapy in head and neck cancer:
A mini-review. Oral Oncol. 87:165–169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lo Russo G, Tessari A, Capece M, Galli G,
de Braud F, Garassino MC and Palmieri D: MicroRNAs for the
diagnosis and management of malignant pleural mesothelioma: A
literature review. Front Oncol. 8:6502018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kuang YS, Wang Y, Ding LD, Yang L, Wang Y,
Liu SH, Zhu BT, Wang XN, Liu HY, Li J, et al: Overexpression of
CREPT confers colorectal cancer sensitivity to fluorouracil. World
J Gastroenterol. 24:475–483. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu T, Li WM, Wang WP, Sun Y, Ni YF, Xing
H, Xia JH, Wang XJ, Zhang ZP and Li XF: Inhibiting CREPT reduces
the proliferation and migration of non-small cell lung cancer cells
by down-regulating cell cycle related protein. Am J Transl Res.
8:2097–2113. 2016.PubMed/NCBI
|
|
44
|
Sun M, Si G, Sun HS and Si FC: Inhibition
of CREPT restrains gastric cancer growth by regulation of cycle
arrest, migration and apoptosis via ROS-regulated p53 pathway.
Biochem Biophys Res Commun. 496:1183–1190. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liang Z, Feng Q, Xu L, Li S and Zhou L:
CREPT regulated by miR-138 promotes breast cancer progression.
Biochem Biophys Res Commun. 493:263–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
